WCN25-3679 Open label, single arm, multicenter, prospective study on oral enteric coated budesonide therapy for primary IgA nephropathy
In recent years, targeted release Budesonide has become the sheet anchor of therapy in the management of IgA nephropathy. In India only an enteric coated formulation (Iganef 9 mg) is available which is also more economical than the target release preparation. This study was conducted to investigate its efficacy on proteinuria reduction and eGFR stabilization in biopsy proven patients with IgA Nephropathy.
Authors
- Vinay Rathore (ORCID: https://orcid.org/0000-0003-4315-5072)
- Hari Shankar Meshram
- Dinesh Khullar (ORCID: https://orcid.org/0000-0003-4276-2575)
- Sanjiv Jasuja (ORCID: https://orcid.org/0000-0003-1707-5650)
- Sanjeev Gulati (ORCID: https://orcid.org/0000-0002-1778-7693)
- Sanshriti Chauhan (ORCID: https://orcid.org/0000-0001-7385-5614)
- Karan Saraf (ORCID: https://orcid.org/0000-0002-6678-2629)
- Arpita Roy Chaudhary
Institutions
- TERI University (IN)
- All India Institute of Medical Sciences Raipur (IN)
- Indraprastha Apollo Hospitals (IN)
- Apollo Hospitals (IN)
- Fortis Healthcare (IN)
- Max Super Speciality Hospital (IN)
- Max Healthcare (IN)
- Asia Pacific Observatory on Health Systems and Policies (IN)
- Institute of Post Graduate Medical Education and Research (IN)
- Fortis Hospital (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.433
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00